Diagnosis of hypochondroplasia: international Delphi consensus recommendations

Diagnostic recommendations that integrate clinical, radiographic and genetic approaches to improve recognition and facilitate earlier diagnosis in individuals with hypochondroplasia, and to support optimal care. An…

Thyroid Monitoring After Intravascular Iodinated Contrast Media in Infants and Children Through 3 Years of Age

This is a multi-society joint statement summarizing the evidence and consensus recommendations regarding thyroid function monitoring after administration of intravascular iodinated contrast in young children.

International Consensus Guidelines on the Implementation and Monitoring of Vosoritide Therapy in Individuals with Achondroplasia

Since the approval of vosoritide in 2021, a need was created for a treatment guideline for support clinicians. An international collaborative of leading experts and patient…

International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia

Achondroplasia is the most common skeletal dysplasia and is characterized by a variety of medical, functional and psychosocial challenges across the lifespan. There is variability in…

PES Statement on Thyroid Monitoring in Infants and Young Children Receiving Iodine-Containing Contrast Media

Position Statement on Genital Surgery in Individuals with Differences of Sex Development (DSD)/Intersex Traits

Balancing the Benefits and Harms of Thyroid Cancer Surveillance in Survivors of Childhood, Adolescent and Young Adult Cancer: Recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration with the PanCareSurFup Consortium (Cancer Treat Rev. 2018)

An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of PCOS in Adolescence (HRP 2017)

An International Consortium Update on the Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence,

Revised D&T Statement on GnRHa and Prolonged QT 2017

PES Drugs and Therapeutics Committee presents a statement on the Risk of Prolonged QT Interval with Gonadotropin Releasing Hormone Agonists.

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report